Last reviewed · How we verify
AGN-229666
AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates gene expression to reduce inflammation and promote tissue repair.
AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates gene expression to reduce inflammation and promote tissue repair. Used for Dry eye disease, Meibomian gland dysfunction.
At a glance
| Generic name | AGN-229666 |
|---|---|
| Sponsor | Allergan |
| Drug class | Retinoid X receptor (RXR) agonist |
| Target | RXR (Retinoid X Receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Dermatology |
| Phase | Phase 3 |
Mechanism of action
RXR agonists activate retinoid X receptors, which are nuclear receptors involved in regulating inflammatory pathways and cellular differentiation. By selectively targeting RXR, AGN-229666 aims to suppress inflammatory responses while promoting healing, particularly in ocular and dermatological conditions. This mechanism allows modulation of immune and epithelial cell function without the systemic effects associated with broader retinoid signaling.
Approved indications
- Dry eye disease
- Meibomian gland dysfunction
Common side effects
- Ocular hyperemia
- Eye irritation
- Blurred vision
Key clinical trials
- AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis (PHASE3)
- AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis (PHASE3)
- AGN-229666 for the Treatment of Allergic Conjunctivitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |